FIGURES





Figure 1. **Average serum concentrations of mirikizumab during the induction period in the study described in Example 1.**



Abbreviations: IV = intravenous; PK = pharmacokinetics; SC = subcutaneous.

Figure 2. **Average serum concentrations of mirikizumab during the maintenance period in the study described in Example 1.**




Figure 3. **Population pharmacokinetic model-estimated clearance versus body weight in the study of Example 1.**

5





Figure 4. **Population pharmacokinetic model-estimated central volume of distribution versus body weight in the study of Example 1.**


5



Abbreviation: PI = Prediction interval

Figure 5. **Visual predictive check of model fit of Week 12 endoscopic response in the study of Example 1.**


5



Abbreviation: PI = Prediction interval

Figure 6. **Visual predictive check of model fit of Week 12 endoscopic remission in the study of Example 1.**

5



Abbreviation: PI = Prediction interval

Figure 7. **Simulation of endoscopic response and endoscopic remission rates at Week 12 for mirikizumab doses and exposures of interest for the study of Example 2.**